Rakovina Therapeutics
VerifiedThis company is developing precision medicines to target and kill cancer cells.
Launch date
Employees
Market cap
CAD7.7m
Net debt
(CAD1.2m)
Enterprise valuation
$7m (Public information from Jun 2024)
Share price
CAD0.11 RKV.V
Vancouver British Columbia (HQ)
| CAD | 2021 | 2022 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $0.0 | round | |
| investor | $0.0 | round | |
| N/A | $0.0 | round | |
* | N/A | $1.5m | Post IPO Equity |
| Total Funding | 000k | ||